Clinical Trial

Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-10; most recent amendment 2026-05-19.
Status change: Not Yet Recruiting → Recruiting 2026-01-29
Trial Details
NCT Number NCT07076862
Lead Sponsor University of California, Davis
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
Conditions PASC Post Acute Sequelae of COVID-19
Enrollment 51 participants
Start Date 2025-12-04
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-22